KLP KAPITALFORVALTNING AS ELVN — Enliven Therapeutics Inc

Ownership history in KLP KAPITALFORVALTNING AS  ·  6 quarters on record

AI Ownership Summary

KLP KAPITALFORVALTNING AS reported Enliven Therapeutics Inc (ELVN) in 6 quarterly 13F filings from 2024 Q4 through 2026 Q1. The latest visible filing shows ELVN at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this ELVN ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was KLP KAPITALFORVALTNING AS's position in Enliven Therapeutics Inc, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

ELVN was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

ELVN stock page KLP KAPITALFORVALTNING AS fund profile KLP KAPITALFORVALTNING AS full holdings
How KLP KAPITALFORVALTNING AS held ELVN — position size vs. price
% of Fund (quarterly)    ELVN price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 6 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 UNCHANGED — — — 6,800 — 0% 0.00% $267K 2026-04-29 $42.40
2025 Q4 UNCHANGED — — — 6,800 — 0% 0.00% $105K 2026-01-28 $25.38
2025 Q3 UNCHANGED — — — 6,800 — 0% 0.00% $139K 2025-10-23 $20.55
2025 Q2 ADDED — — — 6,800 +2,500 +58.1% 0.00% $136K 2025-07-23 $22.35
2025 Q1 UNCHANGED — — — 4,300 — 0% 0.00% $85K 2025-05-06 $19.69
2024 Q4 INITIATED — — — 4,300 — — 0.00% $97K 2025-02-11 $21.41

🏢 Other funds also holding ELVN

As of 2026 Q1 — sorted by position size

Commodore Capital LP 3Y 7.43% ORBIMED ADVISORS LLC 3Y 7Y 6.18% Fairmount Funds Management LLC 3Y 5.25% Jones Hill Capital LP 4.98% Exome Asset Management LLC 4.46% Novo Holdings A/S 3Y 7Y 4.07% Avidity Partners Management LP 3Y 3.73% Vestal Point Capital, LP 3.56% Spruce Street Capital LP 3.1% STEMPOINT CAPITAL LP 2.77%

FAQ About KLP KAPITALFORVALTNING AS and ELVN

These are the practical questions this page is built to answer before you even open the full history table.

How long has KLP KAPITALFORVALTNING AS reported owning ELVN?

KLP KAPITALFORVALTNING AS reported ELVN across 6 quarterly 13F filings, from 2024 Q4 through 2026 Q1.

What was the largest reported ELVN position in KLP KAPITALFORVALTNING AS's portfolio?

The largest reported portfolio weight for ELVN was 0.00% in 2026 Q1.

What is the latest reported ELVN position on this page?

The most recent filing on this page is 2026 Q1, when KLP KAPITALFORVALTNING AS reported 6,800 shares, equal to 0.00% of portfolio, with an estimated market value of $267K.

What does the chart on this ELVN ownership page compare?

The chart compares KLP KAPITALFORVALTNING AS's quarterly ELVN portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to KLP KAPITALFORVALTNING AS Holdings